Rapid solute transport in the peritoneum: Physiologic and clinical consequences

Peritoneal Dialysis International

Volumn 29, Issue SUPPL. 2, 2009, Pages

  Cueto Manzano, Alfonso M ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

High peritoneal transport; Peritoneal physiology; Rapid solute transport

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYALURONIC ACID; ICODEXTRIN; SODIUM; UREA; VERAPAMIL; DIALYSIS FLUID;

AUTOMATION; BIOCOMPATIBILITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIABETES MELLITUS; DIALYSATE; DIASTOLIC BLOOD PRESSURE; FLOW RATE; GLUCOSE ABSORPTION; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; KIDNEY FAILURE; MALNUTRITION; MORTALITY; PATIENT SAFETY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; SOLUTE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ULTRAFILTRATION; ACTIVE TRANSPORT; CHRONIC KIDNEY FAILURE; METABOLISM; PERITONEUM; PHYSIOLOGY; REVIEW; RISK FACTOR; SURVIVAL RATE;

BIOLOGICAL TRANSPORT, ACTIVE; DIALYSIS SOLUTIONS; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONEUM; RISK FACTORS; SURVIVAL RATE;

EID: 67449083769     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902902s17     Document Type: Conference Paper

References (49)

1. Cueto-Manzano AM, Rojas-Campos E. Status of renal replacement therapy and peritoneal dialysis in Mexico. Perit Dial Int 2007; 27:142-8.
2. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
3. Correa-Rotter R, Cueto-Manzano A. The problem of the high transporter: is survival decreased? Perit Dial Int 2001; 21(Suppl 3):S75-9.
4. Davies SJ. Mitigating peritoneal membrane characteristics in modern peritoneal dialysis therapy. Kidney Int Suppl 2006; (103):S76-83.
5. Cueto-Manzano AM, Correa-Rotter R. Is high peritoneal transport rate an independent risk factor for CAPD mortality? Kidney Int 2000; 57:314-20.
6. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11:498-506.
7. Fernández-Reyes MJH, Bajo MA, Hevía C, del Peso G, Ros S, García de Miguel A, et al. Inherent high peritoneal transport and ultrafiltration deficiency: their mid-term clinical relevance. Nephrol Dial Transplant 2007; 22:218-23.
8. Chung SH, Heimburger O, Lindholm B. Poor outcomes for fast transporters on PD: the rise and fall of a clinical concern. Semin Dial 2008; 21:7-10.
9. ter Wee PM, van Ittersum FJ. The new peritoneal dialysis solutions: friends only, or foes in part? Nat Clin Pract Nephrol 2007; 3:604-12.
10. Williams JD, Craig KJ, Topley N, von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
11. Numata M, Nakayama M, Nimura S, Kawakami M, Lindholm B, Kawaguchi Y. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23:116-22.
12. Yáñez-Mó M, Lara-Pezzi E, Selgas R, Ramírez-Huesca M, Domínguez-Jiménez C, Jiménez-Heffernan JA, et al. Peritoneal dialysis induces an epithelial-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-13.
13. del Peso G, Jiménez-Heffernan JA, Bajo MA, Aroeira LS, Aguilera A, Fernández-Perpén A, et al. Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl 2008; (108):S26-33.
14. Axelsson J, Devuyst O, Nordfors L, Heimbürger O, Stenvinkel P, Lindholm B. Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. Kidney Int Suppl 2006; (103):S138-45.
15. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17:2591-8.
16. Holmes C, Mujais S. Glucose sparing in peritoneal dialysis: implications and metrics. Kidney Int Suppl 2006; (103):S104-9.
17. Konings CJ, Kooman JP, Schonck M, Struijk DG, Gladziwa U, Hoorntje SJ, et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 2003; 18:797-803.
18. Tonbul Z, Altintepe L, Sözlü C, Yeksan M, Yildiz A, Türk S. The association of peritoneal transport properties with 24-hour blood pressure levels in CAPD patients. Perit Dial Int 2003; 23:46-52.
19. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990; 37:980-90.
20. Cueto-Manzano AM, Gamba G, Correa-Rotter R. Quantification and characterization of protein loss in continuous ambulatory peritoneal dialysis. Rev Invest Clin 2000; 52: 611-17.
21. Yang WS, Min WK, Park JS, Kim SB. Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients receiving CAPD. Am J Kidney Dis 1997; 30:507-13.
22. Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60:358-63.
23. Cueto-Manzano AM, Quintana-Piña E, Correa-Rotter R. Long-term CAPD survival and analysis of mortality risk factors: 12-year experience of a single center. Perit Dial Int 2001; 21:148-53.
24. Cueto-Manzano AM. Hypoalbuminemia in dialysis. Is it a marker for malnutrition or inflammation? [Spanish]. Rev Invest Clin 2001; 53:152-8.
25. Cueto-Manzano AM, Espinosa A, Hernández A, Correa-Rotter R. Peritoneal transport kinetics correlate with serum albumin but not with the overall nutritional status in CAPD patients. Am J Kidney Dis 1997; 30:229-36.
26. Kang DH, Yoon KI, Choi KB, Lee R, Lee HY, Han DS, et al. Relationship of peritoneal membrane transport characteristics to the nutritional status in CAPD patients. Nephrol Dial Transplant 1999; 14:1715-22.
27. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.
28. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1999; 89:1763-73.
29. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15:953-60.
30. Stenvinkel P, Chung SH, Heimburger O, Lindholm B. Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 2001; 21(Suppl 3):26-9.
31. Cueto-Manzano AM, Salazar M, Valera-Gonzalez I, Rojas-Campos E, Martinez-Ramirez HR, Cortes-Sanabria L, et al. Association between the peritoneal transport rate and systemic inflammation marker in continuous ambulatory peritoneal dialysis [Abstract]. J Am Soc Nephrol 2002; 13: 201A.
32. Pecoits-Filho R, Araújo MR, Lindholm B, Stenvinkel P, Abensur H, Romão JE Jr, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002; 17:1480-6.
33. Rodrigues AS, Almeida M, Fonseca I, Martins M, Carvalho MJ, Silva F, et al. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation. Nephrol Dial Transplant 2002; 17: 1480-6.
34. Chung SH, Heimburger O, Stenvinkel P, Qureshi AR, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 2003; 18:590-7.
35. Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. J Am Soc Nephrol 2006; 17:271-8.
36. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W, et al. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14:2948-57.
37. Cueto-Manzano AM, Rojas-Campos E, Martínez-Ramírez HR, Valera-González I, Medina M, Monteón F, et al. Can the inflammation markers of patients with high peritoneal permeability on continuous ambulatory peritoneal dialysis be reduced on nocturnal intermittent peritoneal dialysis? Perit Dial Int 2006; 26:341-8.
38. Araújo Teixeira MR, Pecoits-Filho RF, Romão Junior JE, Sabbaga E, Marcondes MM, Abensur H. The relationship between ultrafiltrate volume with icodextrin and peritoneal transport pattern according to the peritoneal equilibration test. Perit Dial Int 2002; 22:229-33.
39. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AN, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-44.
40. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546-54.
41. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63:1556-63.
42. Konings CJ, Kooman JP, Gladziwa U, van der Sande FM, Leunissen KM. A decline in residual glomerular filtration during the use of icodextrin may be due to under-hydration. Kidney Int 2005; 67:1190-1.
43. United States, Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Potential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS), January - March 2008 [Web page]. Rockville, MD: FDA; 5 September 2008. [Available at: www.fda.gov/cder/aers/potential_signals/ potential_signals_2008Q1.htm; accessed 15 June 2008]
44. Moberly JB, Sorkin M, Kucharski A, Ogle K, Mongoven J, Skoufos L, et al. Effects of intraperitoneal hyaluronan on peritoneal fluid and solute transport in peritoneal dialysis patients. Perit Dial Int 2003; 23:63-73.
45. Rojas-Campos E, Cortés-Sanabria L, Martínez-Ramírez HR, González L, Martín-del-Campo F, González-Ortiz M, et al. Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2005; 25:576-82.
46. Kolesnyk I, Dekker FW, Noordzij M, le Cessie S, Struijk DG, Krediet RT. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 2007; 27:446-53.
47. Schaefer F, Klaus G, Mehls O, and the Mid-European Pediatric Peritoneal Dialysis Study Group. Peritoneal transport properties and dialysis dose affect growth and nutritional status in children on chronic peritoneal dialysis. J Am Soc Nephrol 1999; 10:1786-92.
48. Ziólkowska H, Panczyk-Tomaszewska M, Debinski A, Sawicki A, Roszkowska-Blaim M. Bone metabolism and peritoneal membrane transport in children on chronic peritoneal dialysis. Perit Dial Int 2003; 23:487-92.
49. Kang DH, Yoon K, Lee HY, Han DS. Impact of peritoneal membrane transport characteristics on acid-base status in CAPD patients. Perit Dial Int 1998; 18:294-302.